Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab What should we report? Lessons learnt from the development and implementation of serious adverse event reporting procedures in non pharmacological trials in palliative care BMC Palliative Care Springer Nature Link Multisystem Immune Related Adverse Events from Dual Agent Immunotherapy Use CJC 1295 Side Effects, Complications, and Risk Profile